Clinical Trial Update: Study Evaluating Etanercept in the Treatment of Subjects With Ankylosing Spondylitis [Phase 3]

View source ↗

Summary

Wyeth (now Pfizer) completed a Phase 3 trial evaluating etanercept for ankylosing spondylitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• ENBREL (etanercept)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Ankylosing Spondylitis | Phase 3 | Status: COMPLETED